Organization (Academic)
Hannover Medical School
ClinicalTrials.gov lists Hannover Medical School as lead sponsor of 202 trials. It has 24 active development programs and 140 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 10 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 13 in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Hannover Medical School: 202 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (243)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Inflammation | 12 |
| Heart Failure | 9 |
| Sepsis | 9 |
| Diabetes Mellitus | 8 |
| Fibrosis | 8 |
Showing 5 of 243 disease areas.
Trials by start year as sponsor or collaborator (29)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 10 |
| 2025 | 10 |
| 2024 | 17 |
| 2023 | 11 |
| 2022 | 8 |
| 2021 | 18 |
| 2020 | 13 |
| 2019 | 13 |
| 2018 | 16 |
| 2017 | 17 |
Showing 10 of 29 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; 7 of 9 predicted trials reach the 36-month horizon; registered median of 24 months across 109 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (24)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| EVEROLIMUS | Hereditary Sensory and Autonomic Neuropathies | Phase 3 | 1 |
| EVEROLIMUS | Polyneuropathies | Phase 3 | 1 |
| Tacrolimus or Cyclosporine | Polyneuropathies | Phase 3 | 1 |
| Tacrolimus or Cyclosporine | Hereditary Sensory and Autonomic Neuropathies | Phase 3 | 1 |
| Application of T-lymphocytes | Encephalitis | Phase 2 | 1 |
Showing 5 of 24 active programs.
Approved assets (140)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ferric maltol 30 mg (Feraccru®) | 3 |
| GLIMEPIRIDE | 2 |
| EMPAGLIFLOZIN | 2 |
| OBV/PTV/r and DSV | 1 |
| Aerosolized iloprost | 1 |
Showing 5 of 140 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 55% hit target (n=40) | 26% on time (n=42) |
Journals published in (355)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The European respiratory journal | 19 |
| Respiratory research | 16 |
| The New England journal of medicine | 16 |
| American journal of respiratory and critical care medicine | 11 |
| Lancet (London, England) | 11 |
Showing 5 of 355 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 85 | 30 | 2025-12-30 |
Financing and grant events (1)
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-19 | NIH grant | 34,020 | Reporter |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Medizinische Hochschule Hannover | Hanover, DE | EMA | |
| Medizinische Hochschule Hannover | Hanover, DE | EMA |
Organization relationships (381)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Charite University, Berlin, Germany | Co sponsors trial with | 10 |
| University Hospital Münster | Co sponsors trial with | 7 |
| Medical University of Vienna | Co sponsors trial with | 7 |
| Essen University Hospital | Co sponsors trial with | 6 |
| Universität Hamburg | Co sponsors trial with | 6 |
Showing 5 of 381 relationships.
Latest dated events (393)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 393 events.
Biomarker capability evidence (847)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCA3 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABCA4 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABCB11 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABCB4 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ABCC2 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
Showing 5 of 847 evidence rows.
Biomarkers this organization publishes on (1,199)
Shown in this order: most publications first.
Showing 5 of 1,199 biomarkers.
On Scientist.com
Hannover Medical School is listed as a research supplier in the Scientist.com network.
Service areas
Hannover Medical School focuses on research in anatomy, biochemistry, pathology, genetics, pharmacology, and toxicology.
- Website
- www.mhh.de
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Hannover Medical School on Scientist.com
For prices, more details, or to contact Hannover Medical School, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.